<p><em>Evoke 股东每股获得 11.00 美元现金</em></p>
<p>, /PRNewswire/ -- Evoke Pharma, Inc.（前称 NASDAQ: EVOK）（&#34;Evoke&#34;）与 QOL Medical, LLC（&#34;QOL Medical&#34;）今天宣布，由 QOL-EOS Merger Sub, Inc.（一家特拉华州公司，QOL Medical 的直接全资子公司）（&#34;Merger Sub&#34;）发起的收购要约（&#34;要约&#34;），旨在以每股 11.00 美元现金（&#34;要约价格&#34;）收购 Evoke 所有已发行的普通股（面值每股 0.0001 美元）（&#34;股份&#34;），在扣除任何适用的预扣税且不计利息的情况下，于 2025 年 12 月 15 日纽约时间晚上 11:59 过后一分钟到期（&#34;到期时间&#34;），且未被延长。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/591825/QOL_Med_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/591825/QOL_Med_Logo.jpg"/></p>
<p>作为要约的存托机构，Broadridge Corporate Issuer Solutions, LLC 通知，截至到期时间，约有 1,164,862 股股份有效提交且未有效撤回，约占到期时间前已发行和流通股份的 67.63%。</p>
<p>在要约完成后，Merger Sub 与 Evoke 合并（&#34;合并&#34;），所有未在要约中有效提交的股份被取消并转换为获得要约价格的权利（需行使评估权利）。因此，Evoke 成为 QOL Medical 的全资子公司。在 2025 年 12 月 17 日纳斯达克证券市场（&#34;纳斯达克&#34;）开盘前，Evoke 的所有普通股已停止在纳斯达克交易，Evoke 打算迅速使这些股份从纳斯达克退市并根据《1934 年证券交易法》进行注销。</p>
<p><strong>关于 QOL Medical, LLC</strong></p>
<p>QOL Medical 是一家专注于罕见疾病解决方案的专业生物制药公司。成立于 2003 年，QOL Medical 专注于通过收购和商业化孤儿药和胃肠道产品，改善临床结果并提升罕见疾病患者的生活质量，尤其是在服务不足的市场。了解更多信息请访问 <strong>www.qolmed.com.</strong></p>
<p><strong>关于 Evoke Pharma, Inc.</strong></p>
<p>Evoke 是一家专注于开发治疗胃肠道疾病药物的专业制药公司。该公司开发、商业化并销售 GIMOTI，这是一种用于缓解成人急性和复发性糖尿病胃轻瘫症状的美托克洛普拉米德鼻用喷雾剂。</p>
<p>糖尿病胃轻瘫是一种影响全球数百万患者的胃肠道疾病，患者的胃排空时间过长，导致严重的胃肠道症状以及其他系统性并发症。胃轻瘫引起的胃排空延迟可能会影响口服药物的吸收。在 FDA 批准 GIMOTI 商业化之前，美托克洛普拉米德仅以口服和注射剂型提供，并且仍然是目前在美国唯一批准用于治疗胃轻瘫的药物。</p>
<p><strong>关于 Gimoti®（美托克洛普拉米德）鼻用喷雾剂</strong></p>
<p>GIMOTI 适用于缓解成人急性和复发性糖尿病胃轻瘫的症状。重要安全信息：</p>
<p>警告：迟发性运动障碍</p>
<ul>
<li>美托克洛普拉米德可能导致迟发性运动障碍（TD），这是一种严重的运动障碍，通常是不可逆的。治疗持续时间和总累积剂量越长，发生 TD 的风险越高。</li>
<li>对于出现 TD 征兆或症状的患者，应停止使用 GIMOTI。在某些患者中，停止使用美托克洛普拉米德后，症状可能会减轻或消失。</li>
<li>由于长期使用增加了发生 TD 的风险，应避免使用美托克洛普拉米德（所有剂型和给药途径）超过 12 周。</li>
</ul>
<p>GIMOTI 不推荐用于：</p>
<ul>
<li>儿童患者，因存在发展迟发性运动障碍（TD）和其他锥体外症状的风险，以及新生儿存在高铁血红蛋白症的风险。</li>
<li>中度或重度肝功能不全（Child-Pugh B 或 C）、中度或重度肾功能不全（肌酐清除率低于 60 mL/分钟），以及同时使用强 CYP2D6 抑制剂的患者，因存在增加药物暴露和不良反应的风险。</li>
</ul>
<p>GIMOTI 禁忌：</p>
<ul>
<li>有迟发性运动障碍（TD）或对美托克洛普拉米德有肌张力障碍反应的患者。</li>
<li>当刺激胃肠道运动可能危险时（例如，存在胃肠道出血、机械性阻塞或穿孔时）。</li>
<li>患有嗜铬细胞瘤或其他释放儿茶酚胺的副神经节瘤的患者。美托克洛普拉米德可能导致高血压/嗜铬细胞瘤危机，可能是由于肿瘤释放儿茶酚胺所致。</li>
<li>患有癫痫的患者。美托克洛普拉米德可能增加癫痫发作的频率和严重性。</li>
<li>对美托克洛普拉米德过敏的患者。反应包括喉头和舌头水肿及支气管痉挛。</li>
</ul>
<p>与美托克洛普拉米德相关的潜在不良反应包括：迟发性运动障碍（TD）、其他锥体外效应（EPS）、帕金森症症状、运动不安、神经性恶性综合症（NMS）、抑郁、自杀意念和自杀、高血压、液体潴留、高泌乳素血症、对驾驶和操作机械能力的影响。GIMOTI 最常见的不良反应（≥5%）为：味觉障碍、头痛和疲劳。这些并不是 GIMOTI 所有可能的副作用。请咨询医生以获取有关是否应使用 GIMOTI 及其可能的风险因素和副作用的医疗建议。鼓励您向 FDA 报告处方药的负面副作用。</p>
<p>访问 www.fda.gov/medwatch 或拨打 1-800-FDA-1088。</p>
<p><strong>前瞻性声明</strong></p>
<p>Evoke、QOL Medical 和 Merger Sub 提醒您，本新闻稿中包含的非历史事实的陈述为前瞻性陈述。在某些情况下，您可以通过诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性陈述。这些前瞻性陈述基于各方当前的信念和期望，包括但不限于：关于向前 Evoke 股东支付和支付报价的时间以及股票的退市和注销能力和时间的陈述。前瞻性陈述的包含不应被视为 Evoke、QOL Medical 或 Merger Sub 对其各自计划将实现的陈述。由于 Evoke 和 QOL Medical 的业务及交易中固有的风险和不确定性，实际结果可能与本新闻稿中所列结果有所不同，包括但不限于：支付或退市或注销的时间可能会延迟；以及与 Evoke 的业务相关的其他风险和不确定性，包括在 Evoke 之前的新闻稿和其向 SEC 提交的定期报告中详细列出的风险和不确定性，以及 QOL Medical 和 Merger Sub 提交的收购要约材料以及 Evoke 在收购要约中提交的征求/推荐声明。</p>
<p>您被提醒不要对这些前瞻性陈述过于依赖，这些陈述仅在本日期时有效。所有前瞻性陈述均完全受此警示声明的限制，Evoke、QOL Medical 或 Merger Sub 均不承担任何义务修订或更新这些陈述，以反映本日期之后的事件或情况，法律要求的情况除外。此警示是根据 1995 年《私人证券诉讼改革法》的安全港条款作出的。</p>
<p><strong>QOL Medical 投资者与媒体联系：</strong> Chelsea King</p>
<p>QOL Medical, LLC</p>
<p>电话：866-469-3773 x1091</p>
<p>cking@qolmed.com</p>
<p>来源：QOL Medical, LLC</p>

EVOK

<p>Evoke Pharma 和 QOL Medical 宣布 QOL-EOS Merger Sub 提出的收购 Evoke 股票的要约已于 2025 年 12 月 15 日到期，收购价格为每股 11.00 美元。此次要约的有效股份为 67.63%。合并后，Evoke 成为 QOL Medical 的全资子公司，其股票已从纳斯达克退市</p>

<p><em>Evoke Stockholders Received $11.00 Per Share in Cash</em></p>
<div class="lb-trans"><p><em>Evoke 股东每股获得 11.00 美元现金</em></p>
</div><p>, /PRNewswire/ -- Evoke Pharma, Inc. (formerly NASDAQ: EVOK) (&#34;Evoke&#34;) and QOL Medical, LLC (&#34;QOL Medical&#34;) today announced that the tender offer (the &#34;Offer&#34;) by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical (the &#34;Merger Sub&#34;), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the &#34;Shares&#34;), of Evoke, in exchange for $11.00 in cash per share (the &#34;Offer Price&#34;), subject to any applicable withholding and without interest thereon, expired at one minute past 11:59 p.m., New York City Time, on December 15, 2025 (the &#34;Expiration Time&#34;) and was not extended.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Evoke Pharma, Inc.（前称 NASDAQ: EVOK）（&#34;Evoke&#34;）与 QOL Medical, LLC（&#34;QOL Medical&#34;）今天宣布，由 QOL-EOS Merger Sub, Inc.（一家特拉华州公司，QOL Medical 的直接全资子公司）（&#34;Merger Sub&#34;）发起的收购要约（&#34;要约&#34;），旨在以每股 11.00 美元现金（&#34;要约价格&#34;）收购 Evoke 所有已发行的普通股（面值每股 0.0001 美元）（&#34;股份&#34;），在扣除任何适用的预扣税且不计利息的情况下，于 2025 年 12 月 15 日纽约时间晚上 11:59 过后一分钟到期（&#34;到期时间&#34;），且未被延长。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/591825/QOL_Med_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/591825/QOL_Med_Logo.jpg"/></p>
<p>Broadridge Corporate Issuer Solutions, LLC, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 1,164,862 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 67.63% of the issued and outstanding Shares immediately prior to the Expiration Time.</p>
<div class="lb-trans"><p>作为要约的存托机构，Broadridge Corporate Issuer Solutions, LLC 通知，截至到期时间，约有 1,164,862 股股份有效提交且未有效撤回，约占到期时间前已发行和流通股份的 67.63%。</p>
</div><p>Following the consummation of the Offer, Merger Sub merged with and into Evoke (the &#34;Merger&#34;), and all Shares that had not been validly tendered in the Offer were canceled and converted into the right to receive the Offer Price (subject to the exercise of appraisal rights). As a result of the Merger, Evoke became a wholly owned subsidiary of QOL Medical. Prior to the opening of trading on The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) on December 17, 2025, all shares of Evoke common stock have ceased trading on Nasdaq, and Evoke intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.</p>
<div class="lb-trans"><p>在要约完成后，Merger Sub 与 Evoke 合并（&#34;合并&#34;），所有未在要约中有效提交的股份被取消并转换为获得要约价格的权利（需行使评估权利）。因此，Evoke 成为 QOL Medical 的全资子公司。在 2025 年 12 月 17 日纳斯达克证券市场（&#34;纳斯达克&#34;）开盘前，Evoke 的所有普通股已停止在纳斯达克交易，Evoke 打算迅速使这些股份从纳斯达克退市并根据《1934 年证券交易法》进行注销。</p>
</div><p><strong>About QOL Medical, LLC</strong></p>
<div class="lb-trans"><p><strong>关于 QOL Medical, LLC</strong></p>
</div><p>QOL Medical is a specialty biopharmaceutical company committed to delivering solutions for rare diseases. Founded in 2003, QOL Medical focuses on improving clinical outcomes and enhancing the quality of life for patients with rare diseases through the acquisition and commercialization of orphan and gastrointestinal products in underserved markets. Learn more at <strong>www.qolmed.com.</strong></p>
<div class="lb-trans"><p>QOL Medical 是一家专注于罕见疾病解决方案的专业生物制药公司。成立于 2003 年，QOL Medical 专注于通过收购和商业化孤儿药和胃肠道产品，改善临床结果并提升罕见疾病患者的生活质量，尤其是在服务不足的市场。了解更多信息请访问 <strong>www.qolmed.com.</strong></p>
</div><p><strong>About Evoke Pharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Evoke Pharma, Inc.</strong></p>
</div><p>Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.</p>
<div class="lb-trans"><p>Evoke 是一家专注于开发治疗胃肠道疾病药物的专业制药公司。该公司开发、商业化并销售 GIMOTI，这是一种用于缓解成人急性和复发性糖尿病胃轻瘫症状的美托克洛普拉米德鼻用喷雾剂。</p>
</div><p>Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.</p>
<div class="lb-trans"><p>糖尿病胃轻瘫是一种影响全球数百万患者的胃肠道疾病，患者的胃排空时间过长，导致严重的胃肠道症状以及其他系统性并发症。胃轻瘫引起的胃排空延迟可能会影响口服药物的吸收。在 FDA 批准 GIMOTI 商业化之前，美托克洛普拉米德仅以口服和注射剂型提供，并且仍然是目前在美国唯一批准用于治疗胃轻瘫的药物。</p>
</div><p><strong>About Gimoti® (metoclopramide) nasal spray</strong></p>
<div class="lb-trans"><p><strong>关于 Gimoti®（美托克洛普拉米德）鼻用喷雾剂</strong></p>
</div><p>GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information:</p>
<div class="lb-trans"><p>GIMOTI 适用于缓解成人急性和复发性糖尿病胃轻瘫的症状。重要安全信息：</p>
</div><p>WARNING: TARDIVE DYSKINESIA</p>
<div class="lb-trans"><p>警告：迟发性运动障碍</p>
</div><ul>
<li>Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.</li>
<li>Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.</li>
<li>Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use <em>.</em></li>
</ul>
<div class="lb-trans"><ul>
<li>美托克洛普拉米德可能导致迟发性运动障碍（TD），这是一种严重的运动障碍，通常是不可逆的。治疗持续时间和总累积剂量越长，发生 TD 的风险越高。</li>
<li>对于出现 TD 征兆或症状的患者，应停止使用 GIMOTI。在某些患者中，停止使用美托克洛普拉米德后，症状可能会减轻或消失。</li>
<li>由于长期使用增加了发生 TD 的风险，应避免使用美托克洛普拉米德（所有剂型和给药途径）超过 12 周。</li>
</ul>
</div><p>GIMOTI is not recommended for use in:</p>
<div class="lb-trans"><p>GIMOTI 不推荐用于：</p>
</div><ul>
<li>Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates <em>.</em></li>
<li>Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.</li>
</ul>
<div class="lb-trans"><ul>
<li>儿童患者，因存在发展迟发性运动障碍（TD）和其他锥体外症状的风险，以及新生儿存在高铁血红蛋白症的风险。</li>
<li>中度或重度肝功能不全（Child-Pugh B 或 C）、中度或重度肾功能不全（肌酐清除率低于 60 mL/分钟），以及同时使用强 CYP2D6 抑制剂的患者，因存在增加药物暴露和不良反应的风险。</li>
</ul>
</div><p>GIMOTI is contraindicated:</p>
<div class="lb-trans"><p>GIMOTI 禁忌：</p>
</div><ul>
<li>In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.</li>
<li>When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).</li>
<li>In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.</li>
<li>In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.</li>
<li>In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.</li>
</ul>
<div class="lb-trans"><ul>
<li>有迟发性运动障碍（TD）或对美托克洛普拉米德有肌张力障碍反应的患者。</li>
<li>当刺激胃肠道运动可能危险时（例如，存在胃肠道出血、机械性阻塞或穿孔时）。</li>
<li>患有嗜铬细胞瘤或其他释放儿茶酚胺的副神经节瘤的患者。美托克洛普拉米德可能导致高血压/嗜铬细胞瘤危机，可能是由于肿瘤释放儿茶酚胺所致。</li>
<li>患有癫痫的患者。美托克洛普拉米德可能增加癫痫发作的频率和严重性。</li>
<li>对美托克洛普拉米德过敏的患者。反应包括喉头和舌头水肿及支气管痉挛。</li>
</ul>
</div><p>Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.</p>
<div class="lb-trans"><p>与美托克洛普拉米德相关的潜在不良反应包括：迟发性运动障碍（TD）、其他锥体外效应（EPS）、帕金森症症状、运动不安、神经性恶性综合症（NMS）、抑郁、自杀意念和自杀、高血压、液体潴留、高泌乳素血症、对驾驶和操作机械能力的影响。GIMOTI 最常见的不良反应（≥5%）为：味觉障碍、头痛和疲劳。这些并不是 GIMOTI 所有可能的副作用。请咨询医生以获取有关是否应使用 GIMOTI 及其可能的风险因素和副作用的医疗建议。鼓励您向 FDA 报告处方药的负面副作用。</p>
</div><p>Visit www.fda.gov/medwatch or call 1-800-FDA-1088.</p>
<div class="lb-trans"><p>访问 www.fda.gov/medwatch 或拨打 1-800-FDA-1088。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Evoke, QOL Medical and Merger Sub caution you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;contemplates,&#34; &#34;believes,&#34; &#34;estimates,&#34; &#34;predicts,&#34; &#34;potential&#34; or &#34;continue&#34; or the negatives of these terms or other similar expressions. The forward-looking statements are based on the parties' current beliefs and expectations and include, but are not limited to: statements regarding the payment and timing of payment of the Offer Price to former Evoke stockholders and the ability and timing of delisting and deregistration of the Shares. The inclusion of forward-looking statements should not be regarded as a representation by Evoke, QOL Medical or Merger Sub that any of their respective plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke's and QOL Medical's businesses and the transactions, including, without limitation: that the timing of the payment or delisting or deregistration may be delayed; and other risks and uncertainties pertaining to Evoke's business, including the risks and uncertainties detailed in Evoke's prior press releases and in the periodic reports it files with the SEC, as well as the tender offer materials filed by QOL Medical and Merger Sub and the Solicitation/Recommendation Statement filed by Evoke in connection with the tender offer.</p>
<div class="lb-trans"><p>Evoke、QOL Medical 和 Merger Sub 提醒您，本新闻稿中包含的非历史事实的陈述为前瞻性陈述。在某些情况下，您可以通过诸如 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜在” 或 “继续” 等术语或这些术语的否定形式或其他类似表达来识别前瞻性陈述。这些前瞻性陈述基于各方当前的信念和期望，包括但不限于：关于向前 Evoke 股东支付和支付报价的时间以及股票的退市和注销能力和时间的陈述。前瞻性陈述的包含不应被视为 Evoke、QOL Medical 或 Merger Sub 对其各自计划将实现的陈述。由于 Evoke 和 QOL Medical 的业务及交易中固有的风险和不确定性，实际结果可能与本新闻稿中所列结果有所不同，包括但不限于：支付或退市或注销的时间可能会延迟；以及与 Evoke 的业务相关的其他风险和不确定性，包括在 Evoke 之前的新闻稿和其向 SEC 提交的定期报告中详细列出的风险和不确定性，以及 QOL Medical 和 Merger Sub 提交的收购要约材料以及 Evoke 在收购要约中提交的征求/推荐声明。</p>
</div><p>You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and none of Evoke, QOL Medical or Merger Sub undertake any obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</p>
<div class="lb-trans"><p>您被提醒不要对这些前瞻性陈述过于依赖，这些陈述仅在本日期时有效。所有前瞻性陈述均完全受此警示声明的限制，Evoke、QOL Medical 或 Merger Sub 均不承担任何义务修订或更新这些陈述，以反映本日期之后的事件或情况，法律要求的情况除外。此警示是根据 1995 年《私人证券诉讼改革法》的安全港条款作出的。</p>
</div><p><strong>Investor &amp; Media Contact for QOL Medical:</strong> Chelsea King</p>
<div class="lb-trans"><p><strong>QOL Medical 投资者与媒体联系：</strong> Chelsea King</p>
</div><p>QOL Medical, LLC</p>
<div class="lb-trans"><p>QOL Medical, LLC</p>
</div><p>Tel:866-469-3773 x1091</p>
<div class="lb-trans"><p>电话：866-469-3773 x1091</p>
</div><p>cking@qolmed.com</p>
<div class="lb-trans"><p>cking@qolmed.com</p>
</div><p>SOURCE QOL Medical, LLC</p>
<div class="lb-trans"><p>来源：QOL Medical, LLC</p>
</div>

Evoke Pharma 和 QOL Medical 宣布要约收购已到期 | EVOK 股票新闻